Video

Maintaining Biologic Adherence

What is the value of maintaining beneficial biologic therapy long-term for psoriasis?

Brad Glick, DO, FAAD: I think that really speaks to what the the needs are in managing patients when we have to shift therapies, particularly when there's an insurance shift. Once again, the first bullet point that is most important is to try to maintain the same therapy or the same class. If you can't, then you have to step back and look at the counseling points and determine whether the other categories of therapies whether they be other older systemic therapies, although I prefer to and most of us typically don't go that retro back to older therapies.

But we would go to a different class of biologic therapy and we look at that entire patient, their medication, profile their comorbidities, and choose accordingly and explain the risk and benefit and hopefully patients have equally successful responses when we have to shift to a different agent.


Related Videos
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
The APAC Recap: Cardiomyopathy at CAPP Live 2024 with Greg Duck, PA-C | Image Credit: APAC
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
The APAC Recap: Peripheral Artery Disease at CAPP Live 2024 with Bob Ross, PA-C | Image Credit: APAC
How to Manage Aspirin-Exacerbated Respiratory Disease
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
AMG0001 Advances Healing in CLTI with David G. Armstrong, DPM, PhD, and Michael S. Conte, MD | Image Credit: Canva
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
© 2024 MJH Life Sciences

All rights reserved.